Janet B Serle, MD

Janet B. Serle, MD is Professor Emeritus of Ophthalmology at the Icahn School of Medicine at Mount Sinai.  After graduation from Harvard Medical School, she completed a glaucoma research fellowship, a residency in ophthalmology, and a glaucoma clinical fellowship at the Mount Sinai Medical Center, where she was an active member of the full-time faculty from 1985 through 2018.  During her tenure on the full-time faculty, Dr. Serle was the ophthalmology residency program director at Mount Sinai for over 13 years. She was the Director of both the Glaucoma Clinical and Glaucoma Research Fellowships at the Icahn School of Medicine at Mount Sinai for over 20 years.  Through these positions she trained and mentored well over 150 residents, fellows, graduate students, medical students, college students and high school students.  Many of whom have gone on to have impressive careers.

Dr. Serle has been a leader in many ophthalmic organizations.  She received a Senior Honor Award from the American Academy of Ophthalmology, is a past President of the New York Glaucoma Society, is a past President of the NY chapter of Women in Ophthalmology and is a past President of the New York Society for Clinical Ophthalmology.  She has been the chair of the American Glaucoma Society Financial Audit Committee and the chair of the ARVO Commercial Relationships Committee.

In addition to patient care, Dr. Serle has lectured nationally and internationally, and has been an active researcher.  She has been Principal Investigator on more than 50 N.I.H. and industry sponsored grants and has published over 85 peer reviewed articles and chapters.  Her research has focused on the medical and surgical management of glaucoma.  Dr. Serle presented at the FDA in 2017 which resulted in the approval of the glaucoma drug Netarsudil. Dr. Serle continues to focus on the development of new treatments for glaucoma and working with industry on new drug developments.